Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Oct 21;15(10):e0239338. doi: 10.1371/journal.pone.0239338

Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes

Oliver Reed 1, Ibrahim Jubber 1, Jon Griffin 2, Aidan P Noon 3, Louise Goodwin 1, Syed Hussain 4, Marcus G Cumberbatch 1,5,, James W F Catto 1,3,‡,*
Editor: Amitava Mukherjee6
PMCID: PMC7577448  PMID: 33085669

Abstract

Objectives

Up to 10% of Bladder Cancers may arise following occupational exposure to carcinogens. We hypothesised that different cancer phenotypes reflected different patterns of occupational exposure.

Methods

Consecutive participants, with bladder cancer, self-completed a structured questionnaire detailing employment, tasks, exposures, smoking, lifestyle and family history. Our primary outcome was association between cancer phenotype and occupational details.

Results

We collected questionnaires from 536 patients, of whom 454 (85%) participants (352 men and 102 women) were included. Women were less likely to be smokers (68% vs. 81% Chi sq. p<0.001), but more likely than men to inhale environmental tobacco smoke at home (82% vs. 74% p = 0.08) and use hair dye (56% vs. 3%, p<0.001). Contact with potential carcinogens occurred in 282 (62%) participants (mean 3.1 per worker (range 0–14)). High-grade cancer was more common than low-grade disease in workers from the steel, foundry, metal, engineering and transport industries (p<0.05), and in workers exposed to crack detection dyes, chromium, coal/oil/gas by-products, diesel fumes/fuel/aircraft fuel and solvents (such as trichloroethylene). Higher staged cancers were frequent in workers exposed to Chromium, coal products and diesel exhaust fumes/fuel (p<0.05). Various workers (e.g. exposed to diesel fuels or fumes (Cox, HR 1.97 (95% CI 1.31–2.98) p = 0.001), employed in a garage (HR 2.19 (95% CI 1.31–3.63) p = 0.001), undertaking plumbing/gas fitting/ventilation (HR 2.15 (95% CI 1.15–4.01) p = 0.017), undertaking welding (HR 1.85 (95% CI 1.24–2.77) p = 0.003) and exposed to welding materials (HR 1.92 (95% CI 1.27–2.91) p = 0.002)) were more likely to have disease progression and receive radical treatment than others. Fewer than expected deaths were seen in healthcare workers (HR 0.17 (95% CI 0.04–0.70) p = 0.014).

Conclusions

We identified multiple occupational tasks and contacts associated with bladder cancer. There were some associations with phenotype, although our study design precludes robust assessment.

Introduction

Bladder cancer (BC) is a common human malignancy and one of the most expensive to manage [1]. Most tumours present with haematuria [2] and at diagnosis around 30% are muscle invasive and 70% non-muscle invasive cancers (NMI) [3]. NMI tumours are stratified into low and high grade lesions, to reflect different treatments and outcomes [4]. The majority of BCs are urothelial cell carcinoma (UCC) in histological sub-type and arise following exposure to carcinogens excreted in the urine [5]. The most common bladder carcinogens are found through tobacco smoke [6] or occupation task [7,8]. Risk from smoking varies with gender, duration, tobacco type and mode of inhalation [9,10]. These aetiological factors mean that BCs are most common in older patients, in men and in the Western World [1]. An individual’s risk of BC reflects their carcinogen burden and their ability to metabolise pro-carcinogens [11].

Around 10% of BCs arise following occupational exposure to carcinogens [12]. These carcinogens may be broadly classified into aromatic amines, polycyclic aromatic hydrocarbons (PAHs), heavy metals or mixed compounds [7]. The occupational exposure of workers to many carcinogens has been limited by health and safety regulations [such as the European Union directives (e.g. 90/394/EEC and 98/24/EC) and the 2002 Control of Substances Hazardous to Health Regulations in the UK] and changes in manufacturing. Whilst many high risk urothelial carcinogens have been identified, it is suspected that more are still in use. The uncertainty about and identification of further candidates reflects the long latency between exposure and cancer, variations in an individual’s risk, that many workers also smoke, and that many potential carcinogens are in widespread (such as diesel fumes) or occult use [13].

BC arises in at least two distinct phenotypes, reflecting genomic events [14,15]. Low-grade tumours are characterised by papillary growth patterns, few genetic alterations (e.g. FGFR3 or hTERT mutation) and an indolent behaviour [16]. In contrast, high-grade BC is an aggressive disease with genetic and epigenetic instability [17], and multiple mutations [18]. We hypothesised that the BC phenotypes could reflect different carcinogenic exposures and, in turn, occupational tasks. We explored this hypothesis using a large Scandinavian dataset and found various occupations with different risks for localised and invasive BCs, and higher rates of BC mortality in the building sector [19]. However, this dataset lacked granularity of occupational tasks, personal smoking exposure and classified BC by stage not grade of differentiation.

To build upon our prior work, we undertook a prospective detailed occupation survey using a consecutive cohort of patients arising in a region of high BC risk. We annotated patients with detailed histological and outcome data.

Materials and methods

Patients and occupational questionnaire

Consecutive patients with a new diagnosis of BC treated at the Royal Hallamshire Hospital, Sheffield (RHH), were enrolled from February 2010 to July 2012. RHH is the sole urological service in Sheffield (population 600,000) and the cancer center for South Yorkshire, UK (population 1.9 million). Participants self-completed a structured questionnaire containing questions on employment history, occupational tasks (nature and frequency) and exposures [S1 Fig] over their whole lifetime. The questionnaire was designed in collaboration with Sheffield Occupational health Advisory Service (SOHAS) after systematic review [7,8] and included sections for smoking (direct and passive environmental tobacco smoke (ETS)) [9] hobbies linked to BC [20,21], lifestyle and family cancer history. Patients with non-urothelial BC (e.g. squamous cell or adenocarcinoma) were excluded due to different causative associations. Paper questionnaires were completed at home and returned using a stamp addressed envelope, before uploading to a prospective database. All patients gave informed consent in an ethically approved programme (South Yorkshire Research Ethics Committee approval number 10/H1310/73) agreed by Sheffield Teaching Hospital review board. Occupational classes were assigned using NYK and ISCO-1958 codes (as detailed in [7]). In persons with multiple occupations or those with short duration we selected the 3 occupations of longest duration and a minimum period of 1 year as previously validated [19]. No formal power calculation was performed. This study was an explorative cohort study and so we included all eligible patients in the recruiting time frame and aimed to describe data (to allow future studies to be powered accordingly).

Pathological and clinical outcomes

Tumours were classified by specialist uropathologists using the 1973 WHO and TNM criteria [22]. In participants with multiple BCs, we analysed outcomes with respect to the primary BC. Patients were treated according to local network (http://www.northtrentcancernetwork.nhs.uk/urology.htm) and international guidelines [3]. Outcome data were collected between August and October 2018 using hospital databases [namely Integrated Clinical Environment (ICE), Lorenzo and EDMS software]. We measured tumour behaviour with respect to time following initial treatment and defined recurrence as a subsequent NMI cancer following a similar tumour and progression as an increase in pathological stage. Radical treatment was measured to the date of Radical Surgery or starting Radical radiotherapy. Date of death was defined using death certification.

Statistical analysis

Our primary outcome was the association between BC phenotype (measured as Grade and Stage) and occupational sector, task and exposures. Secondary outcomes were occupational associations with local recurrence, disease progression, radical treatment and mortality. Data were analysed according to participant self-reported questionnaires. Data cleaning clarified missing or unclear parameters, but did not alter returns. Comparisons between occupational exposures and patient/tumour features were performed using Chi-squared tests for categorical and Students T or Mann Whitney U tests for continuous data. Correlation was determined using Pearson’s coefficient. Survival was plotted against time using the Kaplan-Meier method and compared using Cox regression analysis. Patients were censored at last follow up or death. All analysis was performed in SPSS software (version 24.0, SPSS Corp). Statistical tests were two-tailed and significance defined as p<0.05.

Patient and public involvement

The idea for this project arose following discussions with Simon Pickvance, Sheffield Occupational Health Advisory Service (SOHAS) and local patients. SOHAS works with employees affected by occupational health problems and with employers to improve occupational hygiene. We had observed patients with BC and unusual employment tasks (such as the use of crack detection dyes [13]) or high levels of exposure to heavy metals (in soldering or welding tasks). The occupational questionnaire was designed with SOHAS and refined over several iterations using small patient groups.

Results

Patients and tumours

We collected questionnaires from 536 patients, of whom 82 (15%) were excluded as they had either non-urothelial BCs, non-primary BCs, missing follow up (e.g. in another hospital) or histopathological details were incomplete. We had sufficient data on 454 (85%) participants (Table 1), including 352 (78%) men and 102 women (22%). In total, 25% had a first degree relative with cancer and 355 (78%) participants were smokers (including 118 smoking at BC diagnosis). Women were less likely to be smokers (68% vs. 81% Chi sq. p<0.001), but more likely to inhale ETS at home (82% vs. 74% p = 0.08) and use hair dye (56%, p<0.001) than men. Hobbies varied considerably between the sexes, with more men undertaking fishing and model building (Chi sq. p<0.001). BCs were distributed evenly between low (140 (31%)), moderate (140 (31%)) and high grade (174, 38%) lesions. With regards to stage, most cancers were NMI (368 (88%)) at diagnosis, including 191 (42%) that were high risk (either pTis, pT1 or Grade 3 pTa). Following treatment, recurrence was seen in 244/447 (56%), progression in 114/448 (25%), radical treatment in 156/450 (35%) and death in 157/451 (35%) participants at median of 101 months (interquartile range 73–128).

Table 1. Patients and tumours in this report.

Male Female Total Chi Sq. P
Age at diagnosis (Mean ± St dev) 67.0 ±9.3 66.4 ± 11.3     T Test p = 0.58
First degree relative with cancer 0 264 75% 78 77% 342 75%
1 64 18% 15 15% 79 17%
2 19 5% 7 7% 26 6%
3 or more 5 1% 2 2% 7 2% 0.843
Smoking history Non-smoker 66 19% 33 32% 99 22%
Smoker 286 81% 69 68% 355 78% 0.003
Years smoking (Mean ± St dev) 36.7 ± 17.8 34.7 ± 18.2 T Test p = 0.39
Pack years (Mean ± St dev) 35.3 ± 27.4 25.8 ± 20.0 T Test p = 0.008
ETS at home Yes 260 74% 84 82% 344 76%
No 92 26% 18 18% 110 24% 0.078
ETS at work Yes 281 80% 70 69% 351 77%
No 71 20% 32 31% 103 23% 0.017
Fishing Yes 100 28% 7 7% 107 24%
No 252 72% 95 93% 347 76% <0.001
Swimming Yes 104 30% 36 35% 140 31%
No 248 71% 66 65% 314 69% 0.270
Model building Yes 53 15% 1 1% 54 12%
No 299 85% 101 99% 400 88% <0.001
Hair dye use Yes 10 3% 57 56% 67 15%
No 342 97% 45 44% 387 85% <0.001
Phenacetin Yes 9 3% 3 3% 12 3%
No 343 97% 99 97% 442 97% 0.830
Coal tar creams Yes 16 5% 3 3% 19 4%
No 336 96% 99 97% 435 96% 0.480
UCC Grade 1 88 25% 52 51% 140 31%
2 115 33% 25 25% 140 31%
3 149 42% 25 25% 174 38% 0.020
Presence of CIS Yes 46 13% 4 4% 50 11%
No 305 87% 98 96% 403 89% <0.001
UCC Stage pTa 216 62% 77 76% 293 65%
pTis 15 4% 0 0% 15 3%
pT1 75 21% 13 13% 88 20%
pT2-4 44 13% 12 12% 56 12% 0.020
Total 352 78% 102 22% 454 100%

Employers and occupational class

Individual employers were documented in 393 (87%) participants, including an average of 3.2 (St dev. ± 2.7) each for men and 2.3 (± 2.1) for women (T Test p = 0.003). There were considerable differences in employment class between men and women (Table 2). The most common male occupations were in engineering, steel and metal working sectors (40%). Women most commonly worked in the service industries (25%). High grade BC was more common than low grade BC in workers from the steel, foundry, metal, engineering and transport industries (Table 2, p<0.05). With regards to stage, engineering and metal workers had higher than expected risks of high-risk NMIs BCs (pTis and pT1, chi sq. p = 0.02).

Table 2. Occupational class compared to patient sex and tumour phenotype.

  Gender Grade Stage
  Male Female Chi sq P 1 2 3 Chi sq P Ta Tis T1 T2-4 Chi sq P
Coke, coal, power generation 60 (100%) 0 (0%) <0.001 13 (21.6%) 21 (35%) 26 (43.3%) 0.25 34 (57.6%) 2 (3.3%) 13 (22%) 10 (16.9%) 0.58
Coking plant or gas production 34 (100%) 0 (0%)   6 (17.6%) 12 (35.2%) 16 (47%)   21 (63.6%) 2 (6%) 6 (18.1%) 4 (12.1%)  
Coal mining/smokeless fuel making 37 (100%) 0 (0%)   9 (24.3%) 11 (29.7%) 17 (45.9%)   20 (54%) 1 (2.7%) 9 (24.3%) 7 (18.9%)  
Nuclear power 7 (100%) 0 (0%)   2 (28.5%) 1 (14.2%) 4 (57.1%)   4 (57.1%) 0 (0%) 1 (14.2%) 2 (28.5%)  
Steel and foundry 139 (92.6%) 11 (7.3%) <0.001 36 (23.6%) 54 (35.5%) 62 (40.7%) 0.05 90 (59.6%) 8 (5.2%) 35 (23.1%) 18 (11.9%) 0.15
Metal refining 26 (100%) 0 (0%)   4 (15.3%) 9 (34.6%) 13 (50%)   15 (57.6%) 2 (7.6%) 6 (23%) 3 (11.5%)  
Steel industry 100 (93.4%) 7 (6.5%)   27 (24.7%) 35 (32.1%) 47 (43.1%)   59 (54.6%) 7 (6.4%) 27 (25%) 15 (13.8%)  
Steel production 62 (93.9%) 4 (6%)   18 (27.2%) 18 (27.2%) 30 (45.4%)   41 (62.1%) 4 (6%) 12 (18.1%) 9 (13.6%)  
Heat treatment 50 (94.3%) 3 (5.6%)   15 (28.3%) 13 (24.5%) 25 (47.1%)   33 (62.2%) 4 (7.5%) 11 (20.7%) 5 (9.4%)  
Forging 39 (95.1%) 2 (4.8%)   12 (29.2%) 11 (26.8%) 18 (43.9%)   24 (58.5%) 3 (7.3%) 9 (21.9%) 5 (12.1%)  
Foundries 53 (98.1%) 1 (1.8%)   12 (21.8%) 19 (34.5%) 24 (43.6%)   31 (56.3%) 3 (5.4%) 14 (25.4%) 7 (12.7%)  
Engineering and metals 140 (90.3%) 15 (9.6%) <0.001 37 (23.4%) 51 (32.2%) 70 (44.3%) 0.03 92 (58.5%) 9 (5.7%) 39 (24.8%) 17 (10.8%) 0.02
Engineering 84 (91.3%) 8 (8.6%)   22 (23.1%) 36 (37.8%) 37 (38.9%)   55 (58.5%) 5 (5.3%) 21 (22.3%) 13 (13.8%)  
Electroplating 8 (88.8%) 1 (11.1%)   2 (22.2%) 1 (11.1%) 6 (66.6%)   6 (66.6%) 1 (11.1%) 2 (22.2%) 0 (0%)  
Cutlery 25 (75.7%) 8 (24.2%)   9 (27.2%) 7 (21.2%) 17 (51.5%)   22 (66.6%) 0 (0%) 9 (27.2%) 2 (6%)  
Welding 54 (100%) 0 (0%)   5 (8.9%) 23 (41%) 28 (50%)   28 (50%) 6 (10.7%) 17 (30.3%) 5 (8.9%)  
Making electrical contacts/solder 27 (93.1%) 2 (6.8%)   11 (37.9%) 8 (27.5%) 10 (34.4%)   22 (75.8%) 1 (3.4%) 3 (10.3%) 3 (10.3%)  
Soldering 48 (92.3%) 4 (7.6%)   16 (30.1%) 18 (33.9%) 19 (35.8%)   31 (58.4%) 2 (3.7%) 13 (24.5%) 7 (13.2%)  
Other manufacturing 70 (89.7%) 8 (10.2%) 0.01 21 (26.9%) 19 (24.3%) 38 (48.7%) 0.11 45 (57.6%) 4 (5.1%) 18 (23%) 11 (14.1%) 0.46
Refining and recycling 7 (100%) 0 (0%)   2 (28.5%) 0 (0%) 5 (71.4%)   5 (71.4%) 1 (14.2%) 0 (0%) 1 (14.2%)  
Making garments & textiles 3 (33.3%) 6 (66.6%)   4 (44.4%) 1 (11.1%) 4 (44.4%)   5 (55.5%) 0 (0%) 3 (33.3%) 1 (11.1%)  
Spinning synthetic fibre 1 (50%) 1 (50%)   1 (50%) 0 (0%) 1 (50%)   1 (50%) 0 (0%) 1 (50%) 0 (0%)  
Plastic production 17 (100%) 0 (0%)   4 (23.5%) 5 (29.4%) 8 (47%)   10 (58.8%) 1 (5.8%) 4 (23.5%) 2 (11.7%)  
Cement products 30 (100%) 0 (0%)   7 (23.3%) 9 (30%) 14 (46.6%)   17 (56.6%) 1 (3.3%) 9 (30%) 3 (10%)  
Rubber tyre industorry 7 (100%) 0 (0%)   1 (14.2%) 2 (28.5%) 4 (57.1%)   6 (85.7%) 0 (0%) 0 (0%) 1 (14.2%)  
Chemical industry 17 (100%) 0 (0%)   1 (5.8%) 5 (29.4%) 11 (64.7%)   10 (58.8%) 2 (11.7%) 1 (5.8%) 4 (23.5%)  
Petroleum industry 8 (80%) 2 (20%)   3 (30%) 0 (0%) 7 (70%)   5 (50%) 1 (10%) 2 (20%) 2 (20%)  
Services 16 (38%) 26 (61.9%) <0.001 19 (45.2%) 11 (26.1%) 12 (28.5%) 0.11 31 (73.8%) 0 (0%) 6 (14.2%) 5 (11.9%) 0.43
Laundries 6 (54.5%) 5 (45.4%)   4 (36.3%) 3 (27.2%) 4 (36.3%)   8 (72.7%) 0 (0%) 2 (18.1%) 1 (9%)  
Hairdressing 2 (22.2%) 7 (77.7%)   5 (55.5%) 4 (44.4%) 0 (0%)   8 (88.8%) 0 (0%) 1 (11.1%) 0 (0%)  
Health care 11 (39.2%) 17 (60.7%)   13 (46.4%) 6 (21.4%) 9 (32.1%)   20 (71.4%) 0 (0%) 4 (14.2%) 4 (14.2%)  
Farming, gardening 25 (86.2%) 4 (13.7%) 0.25 12 (40%) 7 (23.3%) 11 (36.6%) 0.49 20 (66.6%) 0 (0%) 8 (26.6%) 2 (6.6%) 0.43
Agriculture 18 (94.7%) 1 (5.2%)   7 (36.8%) 4 (21%) 8 (42.1%)   12 (63.1%) 0 (0%) 6 (31.5%) 1 (5.2%)  
Horticulture 15 (83.3%) 3 (16.6%)   9 (47.3%) 6 (31.5%) 4 (21%)   15 (78.9%) 0 (0%) 3 (15.7%) 1 (5.2%)  
Building trade 84 (97.6%) 2 (2.3%) <0.001 23 (26.4%) 30 (34.4%) 34 (39%) 0.54 56 (65.1%) 3 (3.4%) 21 (24.4%) 6 (6.9%) 0.29
Construction 63 (98.4%) 1 (1.5%)   16 (25%) 21 (32.8%) 27 (42.1%)   42 (66.6%) 2 (3.1%) 14 (22.2%) 5 (7.9%)  
Painting 36 (97.2%) 1 (2.7%)   9 (23.6%) 16 (42.1%) 13 (34.2%)   23 (60.5%) 1 (2.6%) 12 (31.5%) 2 (5.2%)  
Transport and related 115 (93.4%) 8 (6.5%) <0.001 27 (21.9%) 40 (32.5%) 56 (45.5%) 0.03 71 (57.7%) 6 (4.8%) 33 (26.8%) 13 (10.5%) 0.05
Garages 42 (95.4%) 2 (4.5%)   6 (13.6%) 18 (40.9%) 20 (45.4%)   22 (50%) 2 (4.5%) 16 (36.3%) 4 (9%)  
Nuclear power 2 (100%) 0 (0%)   0 (0%) 0 (0%) 2 (100%)   1 (50%) 0 (0%) 1 (50%) 0 (0%)  
Driving jobs 85 (94.4%) 5 (5.5%)   18 (20%) 31 (34.4%) 41 (45.5%)   52 (57.7%) 5 (5.5%) 25 (27.7%) 8 (8.8%)  
Warehousing 29 (96.6%) 1 (3.3%)   9 (30%) 7 (23.3%) 14 (46.6%)   16 (53.3%) 0 (0%) 10 (33.3%) 4 (13.3%)  
Engine repairs 36 (100%) 0 (0%)   4 (11.1%) 17 (47.2%) 15 (41.6%)   19 (52.7%) 2 (5.5%) 13 (36.1%) 2 (5.5%)  

Substance exposures

Contact with potential or confirmed bladder carcinogens was reported by 282 (62%) participants (mean 3.1 per worker (range 0–14), Table 3). There were marked differences between the genders reflecting employment patterns. The most common contacts were diesel fumes/fuel (n = 176 (39%)), coal/oil/gas by-products (151 (33%)), solvents (125 (28%)), heavy metals (50 (11%)), coking plant fumes (40 (9%)) and crack detection dyes (31 (7%)). Relatively few participants were exposed to more typical urothelial carcinogens such as textile dyes (28 (6%)), printing inks (30 (7%)), 4-aminobiphenyl/MOCA/DDM/MDA/o-toluidine (4 (1%)) reflecting the manufacturing sectors in Yorkshire. Participants often had contact with multiple, similar substances (e.g. diesel fumes (21%) and diesel fuel (18%, Pearson’s correlation r = 0.80, p<0.001), Cadmium (4%) and Chromium (8%, Pearson’s correlation r = 0.47, p<0.001)). High grade BC was more common than low grade cancer in workers exposed to crack detection dyes, chromium, coal/oil/gas by-products, diesel fumes/fuel/aircraft fuel and solvents (such as trichloroethylene). Higher staged cancers were more frequent than expected in workers exposed to Chromium, coal products and diesel exhaust fumes/fuel (p≦0.05).

Table 3. Substance exposure compared to patient sex and tumour grade/stage.

  Gender Grade Stage  
  Male Female Chi sq P 1 2 3 Chi sq P Ta Tis T1 T2-4 Chi sq P
Dyes 9 (75%) 3 (25%) 0.83 2 (16.6%) 7 (58.3%) 3 (25%) 0.11 10 (83.3%) 0 (0%) 2 (16.6%) 0 (0%) 0.46
    Crack-detection dyes 29 (96.6%) 1 (3.3%) 0.01 4 (12.9%) 16 (51.6%) 11 (35.4%) 0.02 23 (74.1%) 2 (6.4%) 5 (16.1%) 1 (3.2%) 0.28
    Dyeing material 15 (93.7%) 1 (6.2%) 0.11 2 (12.5%) 6 (37.5%) 8 (50%) 0.26 9 (56.2%) 0 (0%) 4 (25%) 3 (18.7%) 0.67
    Any other type of dye or stain 18 (81.8%) 4 (18.1%) 0.62 5 (20.8%) 8 (33.3%) 11 (45.8%) 0.53 13 (54.1%) 0 (0%) 5 (20.8%) 6 (25%) 0.2
Cadmium 16 (88.8%) 2 (11.1%) 0.24 2 (11.1%) 7 (38.8%) 9 (50%) 0.18 8 (44.4%) 1 (5.5%) 7 (38.8%) 2 (11.1%) 0.16
Chromium 29 (90.6%) 3 (9.3%) 0.07 3 (9.3%) 11 (34.3%) 18 (56.2%) 0.02 16 (50%) 3 (9.3%) 6 (18.7%) 7 (21.8%) 0.05
Coal, gas and oil by product chemicals 83 (100%) 0 (0%) <0.001 16 (19.2%) 30 (36.1%) 37 (44.5%) 0.04 47 (56.6%) 2 (2.4%) 20 (24%) 14 (16.8%) 0.25
Gas works sludge 12 (100%) 0 (0%) 0.06 1 (8.3%) 6 (50%) 5 (41.6%) 0.17 7 (58.3%) 1 (8.3%) 1 (8.3%) 3 (25%) 0.33
Coking plant fumes or residues 48 (100%) 0 (0%) <0.001 12 (25%) 13 (27%) 23 (47.9%) 0.34 27 (57.4%) 2 (4.2%) 9 (19.1%) 9 (19.1%) 0.46
Coal or coal products 67 (98.5%) 1 (1.4%) <0.001 18 (26.4%) 17 (25%) 33 (48.5%) 0.17 34 (50%) 3 (4.4%) 18 (26.4%) 13 (19.1%) 0.05
Cooking fumes 23 (58.9%) 16 (41%) <0.001 13 (32.5%) 11 (27.5%) 16 (40%) 0.9 25 (62.5%) 1 (2.5%) 6 (15%) 8 (20%) 0.44
Diesel exhaust fumes 90 (96.7%) 3 (3.2%) <0.001 21 (22.1%) 27 (28.4%) 47 (49.4%) 0.03 49 (51.5%) 7 (7.3%) 24 (25.2%) 15 (15.7%) 0.01
Oily/greasy rust proofing chemicals 62 (95.3%) 3 (4.6%) <0.001 13 (19.4%) 21 (31.3%) 33 (49.2%) 0.05 39 (58.2%) 2 (2.9%) 16 (23.8%) 10 (14.9%) 0.62
Diesel fuel 79 (98.7%) 1 (1.2%) <0.001 13 (16%) 27 (33.3%) 41 (50.6%) <0.001 35 (43.2%) 6 (7.4%) 27 (33.3%) 13 (16%) <0.001
Aircraft fuel 9 (100%) 0 (0%) 0.1 1 (11.1%) 1 (11.1%) 7 (77.7%) 0.05 5 (55.5%) 1 (11.1%) 2 (22.2%) 1 (11.1%) 0.6
DDM or MDA 1 (100%) 0 (0%) 0.6 0 (0%) 1 (100%) 0 (0%) 0.3 1 (100%) 0 (0%) 0 (0%) 0 (0%) 0.9
MOCA 1 (100%) 0 (0%) 0.6 0 (0%) 1 (100%) 0 (0%) 0.3 1 (100%) 0 (0%) 0 (0%) 0 (0%) 0.9
Printers’ ink 25 (83.3%) 5 (16.6%) 0.43 10 (33.3%) 11 (36.6%) 9 (30%) 0.61 20 (66.6%) 0 (0%) 5 (16.6%) 5 (16.6%) 0.64
Solvents e.g. trichloroethylene 112 (91.8%) 10 (8.1%) <0.001 23 (18.4%) 48 (38.4%) 54 (43.2%) <0.001 79 (63.2%) 2 (1.6%) 26 (20.8%) 18 (14.4%) 0.5
Arsenic 9 (90%) 1 (10%) 0.34 2 (20%) 6 (60%) 2 (20%) 0.13 7 (70%) 1 (10%) 1 (10%) 1 (10%) 0.58
Fungicide, wood preservative (e.g. 35 (100%) 0 (0%) <0.001 7 (20%) 9 (25.7%) 19 (54.2%) 0.11 18 (51.4%) 1 (2.8%) 11 (31.4%) 5 (14.2%) 0.27
o-toluidine 2 (100%) 0 (0%) 0.45 1 (50%) 1 (50%) 0 (0%) 0.54 2 (100%) 0 (0%) 0 (0%) 0 (0%) 0.78
4-aminobiphenyl 0 (0%) 0 (0%) NA 0 (0%) 0 (0%) 0 (0%) NA 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA
Ionising radiation (radioactive sources) 11 (91.6%) 1 (8.3%) 0.23 3 (25%) 2 (16.6%) 7 (58.3%) 0.33 6 (50%) 0 (0%) 2 (16.6%) 4 (33.3%) 0.15
Coal tar cream 14 (82.3%) 3 (17.6%) 0.63 8 (47%) 2 (11.7%) 7 (41.1%) 0.17 11 (64.7%) 1 (5.8%) 2 (11.7%) 3 (17.6%) 0.73

Abbreviations: DDM–n-Dodecyl β-D-maltoside, MOCA–Methylene bis 2,4 aniline, MDA– 4,4’-methylenedianiline.

Occupational task

We questioned participants about their direct involvement or close proximity to (‘nearby’) 33 tasks thought to potentially reflect exposure to urothelial carcinogens (Table 4). Tasks were selected from SOHAS prior occupational cancer episodes. In total, 1,370 tasks were identified by 210 participants. The commonest tasks were welding (n = 115 (25%)), making cement (94 (21%), using lubricating/coolant oils (97 (21%)), soldering/brazing (93 (20%)), degreasing (90 (20%)) or involved inhaling fumes from quenching/forging or cooling (174 (38%)). As with substance exposures and occupational class, there were differences in tasks between the sexes and the associated BCs. Cancers of higher than expected grades were seen with welding, the use of mineral oil lubricants, the use of protective resins and with tasks that included diesel contact (all p<0.05). Tasks that included welding, mineral oil lubricants, the use of protective resins and diesel contact also had higher than expected staged cancers (all p<0.05). Conversely, higher stage cancers only were seen with the use of cement and the making of plastic foam.

Table 4. Occupational tasks compared to patient sex and tumour phenotype.

  Gender Grade Stage
  Male Female Chi sq P 1 2 3 Chi sq P Ta Tis T1 T2-4 Chi sq P
Smelting metals 17 (100%) 0 (0%) 0.02 3 (17.6%) 3 (17.6%) 11 (64.7%) 0.07 8 (47%) 2 (11.7%) 5 (29.4%) 2 (11.7%) 0.13
Smelting metals nearby 34 (100%) 0 (0%) <0.001 7 (20%) 8 (22.8%) 20 (57.1%) 0.06 16 (45.7%) 2 (5.7%) 9 (25.7%) 8 (22.8%) 0.07
Assembling and repairing electrical goods 30 (93.7%) 2 (6.2%) 0.02 8 (25%) 9 (28.1%) 15 (46.8%) 0.56 19 (59.3%) 2 (6.2%) 4 (12.5%) 7 (21.8%) 0.21
Assembling and repairing electrical goods nearby 17 (100%) 0 (0%) 0.02 1 (5.8%) 7 (41.1%) 9 (52.9%) 0.07 8 (47%) 0 (0%) 4 (23.5%) 5 (29.4%) 0.12
Making products containing cadmium 5 (100%) 0 (0%) 0.23 2 (33.3%) 0 (0%) 4 (66.6%) 0.21 3 (50%) 1 (16.6%) 2 (33.3%) 0 (0%) 0.18
Making products containing cadmium nearby 7 (100%) 0 (0%) 0.15 1 (14.2%) 3 (42.8%) 3 (42.8%) 0.60 5 (71.4%) 0 (0%) 2 (28.5%) 0 (0%) 0.69
Making or using cement 63 (100%) 0 (0%) <0.001 14 (22.2%) 19 (30.1%) 30 (47.6%) 0.17 31 (50%) 6 (9.6%) 16 (25.8%) 9 (14.5%) <0.001
Making or using cement nearby 29 (93.5%) 2 (6.4%) 0.03 6 (19.3%) 9 (29%) 16 (51.6%) 0.22 16 (55.1%) 1 (3.4%) 8 (27.5%) 4 (13.7%) 0.67
Soldering or brazing 56 (96.5%) 2 (3.4%) <0.001 12 (20.3%) 18 (30.5%) 29 (49.1%) 0.10 31 (52.5%) 2 (3.3%) 15 (25.4%) 11 (18.6%) 0.17
Soldering or brazing nearby 31 (96.8%) 1 (3.1%) 0.01 9 (26.4%) 12 (35.2%) 13 (38.2%) 0.78 22 (64.7%) 2 (5.8%) 5 (14.7%) 5 (14.7%) 0.71
Metal plating 11 (84.6%) 2 (15.3%) 0.54 3 (23%) 3 (23%) 7 (53.8%) 0.50 6 (46.1%) 1 (7.6%) 4 (30.7%) 2 (15.3%) 0.48
Metal plating nearby 10 (100%) 0 (0%) 0.09 3 (30%) 3 (30%) 4 (40%) 0.99 7 (70%) 1 (10%) 1 (10%) 1 (10%) 0.58
Cadmium plating 2 (100%) 0 (0%) 0.45 0 (0%) 2 (100%) 0 (0%) 0.11 2 (100%) 0 (0%) 0 (0%) 0 (0%) 0.78
Cadmium plating nearby 6 (100%) 0 (0%) 0.18 1 (16.6%) 1 (16.6%) 4 (66.6%) 0.35 4 (66.6%) 1 (16.6%) 1 (16.6%) 0 (0%) 0.25
Fumes from quenching (heat treatment) 33 (97%) 1 (2.9%) 0.01 13 (36.1%) 6 (16.6%) 17 (47.2%) 0.16 22 (61.1%) 3 (8.3%) 8 (22.2%) 3 (8.3%) 0.29
Fumes from quenching (heat treatment) nearby 54 (94.7%) 3 (5.2%) <0.001 12 (20.6%) 18 (31%) 28 (48.2%) 0.13 31 (53.4%) 3 (5.1%) 14 (24.1%) 10 (17.2%) 0.25
Fumes from forging 32 (100%) 0 (0%) <0.001 9 (26.4%) 12 (35.2%) 13 (38.2%) 0.78 23 (67.6%) 1 (2.9%) 6 (17.6%) 4 (11.7%) 0.99
Fumes from forging nearby 43 (97.7%) 1 (2.2%) <0.001 9 (19.5%) 14 (30.4%) 23 (50%) 0.13 24 (53.3%) 2 (4.4%) 10 (22.2%) 9 (20%) 0.28
Crack detection /Non-destructive testing 23 (100%) 0 (0%) 0.01 3 (12.5%) 10 (41.6%) 11 (45.8%) 0.13 15 (62.5%) 1 (4.1%) 5 (20.8%) 3 (12.5%) 0.99
Crack detection /Non-destructive testing nearby 19 (95%) 1 (5%) 0.06 2 (10%) 8 (40%) 10 (50%) 0.12 11 (55%) 2 (10%) 3 (15%) 4 (20%) 0.22
Resins in ‘cold box’ techniques in foundries 4 (100%) 0 (0%) 0.28 0 (0%) 2 (50%) 2 (50%) 0.39 2 (50%) 1 (25%) 1 (25%) 0 (0%) 0.09
Resins in ‘cold box’ techniques in foundries nearby 4 (100%) 0 (0%) 0.28 0 (0%) 2 (50%) 2 (50%) 0.39 2 (50%) 0 (0%) 1 (25%) 1 (25%) 0.83
Contact with weld material and steel 65 (98.4%) 1 (1.5%) <0.001 11 (16.1%) 20 (29.4%) 37 (54.4%) <0.001 37 (54.4%) 5 (7.3%) 19 (27.9%) 7 (10.2%) 0.04
Contact with weld material and steel nearby 45 (95.7%) 2 (4.2%) <0.001 7 (14.8%) 19 (40.4%) 21 (44.6%) 0.04 24 (52.1%) 3 (6.5%) 9 (19.5%) 10 (21.7%) 0.09
Fume from producing and using coke, and converting coal to gas. 20 (100%) 0 (0%) 0.01 3 (15%) 5 (25%) 12 (60%) 0.10 10 (50%) 2 (10%) 4 (20%) 4 (20%) 0.20
Fume from producing and using coke, and converting coal to gas. nearby 24 (100%) 0 (0%) 0.01 3 (12.5%) 10 (41.6%) 11 (45.8%) 0.13 11 (45.8%) 1 (4.1%) 8 (33.3%) 4 (16.6%) 0.23
Residues from coke and gas production 23 (95.8%) 1 (4.1%) 0.03 4 (16.6%) 7 (29.1%) 13 (54.1%) 0.18 12 (50%) 2 (8.3%) 7 (29.1%) 3 (12.5%) 0.26
Residues from coke and gas production nearby 18 (100%) 0 (0%) 0.02 5 (27.7%) 4 (22.2%) 9 (50%) 0.55 9 (50%) 1 (5.5%) 6 (33.3%) 2 (11.1%) 0.43
Making or handling plastics 23 (92%) 2 (8%) 0.08 9 (34.6%) 9 (34.6%) 8 (30.7%) 0.72 16 (61.5%) 2 (7.6%) 4 (15.3%) 4 (15.3%) 0.55
Making or handling plastics nearby 13 (92.8%) 1 (7.1%) 0.16 3 (21.4%) 4 (28.5%) 7 (50%) 0.61 9 (64.2%) 1 (7.1%) 1 (7.1%) 3 (21.4%) 0.43
Making or handling rubber products 20 (100%) 0 (0%) 0.01 3 (14.2%) 8 (38%) 10 (47.6%) 0.24 12 (57.1%) 1 (4.7%) 4 (19%) 4 (19%) 0.76
Making or handling rubber products nearby 8 (100%) 0 (0%) 0.13 2 (25%) 3 (37.5%) 3 (37.5%) 0.90 6 (75%) 0 (0%) 0 (0%) 2 (25%) 0.38
Breakdown of resins used to make moulds and cores 15 (100%) 0 (0%) 0.03 2 (13.3%) 5 (33.3%) 8 (53.3%) 0.28 6 (40%) 1 (6.6%) 5 (33.3%) 3 (20%) 0.23
Breakdown of resins used to make moulds and cores nearby 4 (80%) 1 (20%) 0.89 1 (20%) 2 (40%) 2 (40%) 0.84 4 (80%) 0 (0%) 1 (20%) 0 (0%) 0.81
Making chemicals from coal, coke, oil and gas byproducts 17 (100%) 0 (0%) 0.02 4 (23.5%) 3 (17.6%) 10 (58.8%) 0.20 9 (56.2%) 2 (12.5%) 3 (18.7%) 2 (12.5%) 0.22
Making chemicals from coal, coke, oil and gas byproducts nearby 14 (93.3%) 1 (6.6%) 0.14 3 (20%) 6 (40%) 6 (40%) 0.59 10 (66.6%) 0 (0%) 4 (26.6%) 1 (6.6%) 0.72
e.g. additives to aeroplane fuel 3 (100%) 0 (0%) 0.35 2 (66.6%) 0 (0%) 1 (33.3%) 0.34 3 (100%) 0 (0%) 0 (0%) 0 (0%) 0.65
e.g. additives to aeroplane fuel nearby 2 (100%) 0 (0%) 0.45 1 (50%) 1 (50%) 0 (0%) 0.54 2 (100%) 0 (0%) 0 (0%) 0 (0%) 0.78
Mineral oils used as lubricants and coolants 61 (98.3%) 1 (1.6%) <0.001 9 (14.2%) 24 (38%) 30 (47.6%) 0.01 30 (47.6%) 6 (9.5%) 18 (28.5%) 9 (14.2%) 0.00
Mineral oils used as lubricants and coolants nearby 32 (94.1%) 2 (5.8%) 0.02 7 (20.5%) 12 (35.2%) 15 (44.1%) 0.39 21 (63.6%) 0 (0%) 6 (18.1%) 6 (18.1%) 0.53
Making and using resins 28 (100%) 0 (0%) <0.001 3 (10.3%) 13 (44.8%) 13 (44.8%) 0.04 16 (55.1%) 0 (0%) 12 (41.3%) 1 (3.4%) 0.01
Making and using resins nearby 12 (92.3%) 1 (7.6%) 0.20 2 (15.3%) 3 (23%) 8 (61.5%) 0.20 7 (53.8%) 2 (15.3%) 4 (30.7%) 0 (0%) 0.03
Making plastic foam 2 (66.6%) 1 (33.3%) 0.65 2 (66.6%) 0 (0%) 1 (33.3%) 0.34 3 (100%) 0 (0%) 0 (0%) 0 (0%) 0.65
Making plastic foam nearby 6 (100%) 0 (0%) 0.18 1 (16.6%) 3 (50%) 2 (33.3%) 0.56 3 (50%) 2 (33.3%) 1 (16.6%) 0 (0%) 0.00
Degreasing 55 (98.2%) 1 (1.7%) <0.001 12 (20.6%) 20 (34.4%) 26 (44.8%) 0.19 32 (55.1%) 2 (3.4%) 15 (25.8%) 9 (15.5%) 0.41
Degreasing nearby 30 (93.7%) 2 (6.2%) 0.02 7 (21.8%) 11 (34.3%) 14 (43.7%) 0.51 20 (62.5%) 1 (3.1%) 5 (15.6%) 6 (18.7%) 0.69
Dry-cleaning 4 (66.6%) 2 (33.3%) 0.52 0 (0%) 3 (50%) 3 (50%) 0.24 3 (50%) 0 (0%) 2 (33.3%) 1 (16.6%) 0.78
Dry-cleaning nearby 2 (66.6%) 1 (33.3%) 0.65 0 (0%) 0 (0%) 3 (100%) 0.09 2 (66.6%) 0 (0%) 0 (0%) 1 (33.3%) 0.62
Timber treatment 21 (95.4%) 1 (4.5%) 0.04 6 (27.2%) 4 (18.1%) 12 (54.5%) 0.23 13 (59%) 1 (4.5%) 6 (27.2%) 2 (9%) 0.77
Timber treatment nearby 9 (100%) 0 (0%) 0.10 2 (22.2%) 3 (33.3%) 4 (44.4%) 0.84 5 (55.5%) 1 (11.1%) 2 (22.2%) 1 (11.1%) 0.60
Plumbing, gas-fitting, heat and ventilation fitting 29 (100%) 0 (0%) <0.001 5 (17.2%) 7 (24.1%) 17 (58.6%) 0.06 13 (46.4%) 3 (10.7%) 6 (21.4%) 6 (21.4%) 0.03
Plumbing, gas-fitting, heat and ventilation fitting nearby 13 (100%) 0 (0%) 0.05 4 (30.7%) 3 (23%) 6 (46.1%) 0.79 7 (58.3%) 0 (0%) 2 (16.6%) 3 (25%) 0.54
Painting 31 (88.5%) 4 (11.4%) 0.10 9 (25.7%) 15 (42.8%) 11 (31.4%) 0.27 21 (61.7%) 1 (2.9%) 9 (26.4%) 3 (8.8%) 0.72
Painting nearby 18 (90%) 2 (10%) 0.17 4 (20%) 8 (40%) 8 (40%) 0.49 12 (63.1%) 1 (5.2%) 4 (21%) 2 (10.5%) 0.96
Contact with industrial diesel 35 (100%) 0 (0%) <0.001 4 (11.1%) 11 (30.5%) 21 (58.3%) 0.01 13 (36.1%) 4 (11.1%) 14 (38.8%) 5 (13.8%) <0.001
Contact with industrial diesel nearby 11 (100%) 0 (0%) 0.07 2 (18.1%) 3 (27.2%) 6 (54.5%) 0.49 7 (63.6%) 0 (0%) 1 (9%) 3 (27.2%) 0.38
Separated out impurities, ores, scrap or wastes 11 (91.6%) 1 (8.3%) 0.23 3 (25%) 4 (33.3%) 5 (41.6%) 0.90 5 (41.6%) 1 (8.3%) 5 (41.6%) 1 (8.3%) 0.16
Separated out impurities, ores, scrap or wastes nearby 4 (100%) 0 (0%) 0.28 1 (25%) 1 (25%) 2 (50%) 0.89 1 (25%) 0 (0%) 2 (50%) 1 (25%) 0.31
Pesticide and herbicide treatments 10 (100%) 0 (0%) 0.09 2 (20%) 3 (30%) 5 (50%) 0.68 7 (70%) 0 (0%) 2 (20%) 1 (10%) 0.94
Pesticide and herbicide treatments nearby 5 (100%) 0 (0%) 0.23 0 (0%) 2 (40%) 3 (60%) 0.31 1 (20%) 0 (0%) 3 (60%) 1 (20%) 0.10
Burning plastics 10 (100%) 0 (0%) 0.09 3 (30%) 2 (20%) 5 (50%) 0.68 6 (60%) 0 (0%) 2 (20%) 2 (20%) 0.83
Burning plastics nearby 6 (100%) 0 (0%) 0.18 2 (33.3%) 2 (33.3%) 2 (33.3%) 0.97 4 (66.6%) 0 (0%) 1 (16.6%) 1 (16.6%) 0.96
Radiotherapy 4 (66.6%) 2 (33.3%) 0.52 2 (33.3%) 1 (16.6%) 3 (50%) 0.73 3 (50%) 0 (0%) 2 (33.3%) 1 (16.6%) 0.78
Radiotherapy nearby 2 (100%) 0 (0%) 0.45 1 (50%) 1 (50%) 0 (0%) 0.54 2 (100%) 0 (0%) 0 (0%) 0 (0%) 0.78
Industrial radiography 3 (100%) 0 (0%) 0.35 0 (0%) 1 (33.3%) 2 (66.6%) 0.45 1 (33.3%) 0 (0%) 1 (33.3%) 1 (33.3%) 0.58
Industrial radiography nearby 4 (80%) 1 (20%) 0.89 2 (40%) 1 (20%) 2 (40%) 0.85 5 (100%) 0 (0%) 0 (0%) 0 (0%) 0.44

Clinical outcomes and occupational history

We compared the occupational histories with treatment outcomes and observed various interesting associations (Fig 1A–1D). The occupation that was performed for the longest period was the occupation that was used in the analysis when compared to clinical outcomes. For example, workers exposed to diesel fuels or fumes (Cox, HR 1.97 (95% CI 1.31–2.98) p = 0.001), or employed in a garage (HR 2.19 (95% CI 1.31–3.63) p = 0.001) were more likely to have disease progression and receive radical treatment (HR 1.75 (95% CI 1.23–2.47) p = 0.002) than others (Fig 1A and 1B). Participants undertaking plumbing/gas fitting/ventilation were also more likely to have disease progression (HR 2.15 (95% CI 1.15–4.01) p = 0.017) and receive radical treatment (HR 2.28 (95% CI 1.39–3.72) p = 0.003) than expected. Higher than expected progression (HR 2.36 (95% CI 1.19–469) p = 0.014) and radical treatment rates (HR 1.89 (95% CI 1.02–3.49) p = 0.04) were also seen in workers making/handling rubber products, whilst progression and radical treatment was more common in participants undertaking welding (HR 1.85 (95% CI 1.24–2.77) p = 0.003) and exposed to welding materials (HR 1.92 (95% CI 1.27–2.91) p = 0.002), than expected (Fig 1C). Consequently these workers (HR 1.85 (95% CI 1.24–2.77) p = 0.003), and those involved in smelting (HR 1.80 (95% CI 1.11–2.91) p = 0.016), were more likely to receive radical treatment than others. Higher than expected radical treatment rates were also seen in workers making/using cement (HR 1.85 (95% CI 1.24–2.73) p = 0.002). Finally, fewer than expected deaths were seen in healthcare workers (HR 0.17 (95% CI 0.04–0.70) p = 0.014) suggesting improved health (Fig 1D).

Fig 1.

Fig 1

a. Progression free survival of bladder cancer of patients exposed and not exposed to occupational diesel fumes. b. Radical treatment free survival of bladder cancer of patients exposed and not exposed to occupational diesel fumes. c. Radical treatment free survival of bladder cancer of patients exposed and not exposed to occupational welding. d. Overall survival of bladder cancer from patients who were healthcare workers compared to any other form of work.

Discussion

We report the outcomes from BC in consecutive patient cohort recruited in South Yorkshire, UK. We find a variety of workers with BC with high risks for aggressive disease that need radical treatment. There are several key findings that require discussion. Firstly, the occupational classes, tasks and contacts reflect local industrial patterns. Most men were employed in the steel, engineering, mining and building sectors, and few worked in industries more typical for BC (with aromatic amine contact); such as rubber, printing, painting and textile sectors. The carcinogens within our population are likely to be a mixture of PAHs, diesel fumes and combustion products. We did find some aromatic amines in occult use in the engineering and metal industries (such as crack detection dyes for non-destructive testing [13]), but these appeared uncommon. PAH exposure arises through cutaneous contact with lubricants, oils and metal working fluids, or inhalation of fumes or combustion products. Our findings contrast and complement a recent systematic review of occupational BC within the UK we conducted [8]. Within this review of 703,941 persons, we found the highest incidence of BC was in chemical process, rubber and dye workers, whilst electrical, transport and chemical process workers had the highest risks of death from BC. Our current data show that electrical workers have a high risk of developing aggressive BC and focus this risk on tasks such as welding and soldering. Fumes from these tasks contain lead oxide, heavy metals (arsenic, cadmium, chromium and nickel etc.) and colophony (rosin based flux containing acetone and carbon monoxide). Our observations may partly explain the high prevalence and mortality from BC seen in Yorkshire [8].

Secondly, our data support the carcinogenicity of diesel fumes to the urothelium. Previous reports have examined this systematically [23] and in 2012 the IARC classified diesel exhaust fumes as carcinogenic (class 1) to the lung (with ‘sufficient evidence’) and the bladder (with ‘limited evidence’) [24]. We add to these data by showing that contact with diesel fuels and fumes were associated with high grade/high stage BC and higher risks of disease progression. Reflecting employment patterns, diesel contact was more common in men than women, and there was some evidence of a dose interaction with cigarette smoking (workers with diesel exhaust exposure had higher pack years (mean: 41 ± 34) than those without (mean 30 ± 22.9, T test p = 0.008)). Workers with diesel exposure were commonly employed in the welding, soldering, agriculture, building, transport and engine repair sectors, and undertook typical task for these sectors (e.g. driving, mixing cement, welding). It is also worth noting that diesel exposure and garage work can also occur with hobbies, reflecting an additional exposure.

Thirdly, our data suggest that occupational history should be included in the BC care pathway. BC is one of the commonest human cancers and one of the most expensive to manage. Much of this expense is spent on monitoring patients with NMI cancers or in screening people with non-visible haematuria [2,25]. Better targeting of resource, with improved survival, more effective screening and lower costs, could be achieved if patient risk stratification was available [26]. Whilst current guidelines rely on age and extent of haematuria [3], our findings suggest that occupational history could guide clinicians to persons at risk of aggressive BC. For example, screening of a few very-high risk persons, e.g. those with aristolochic acid exposure [27] or employees working with aromatic amines [28] is performed, but our data suggest occupational urothelial carcinogenic exposures are common and could help triage a population (by focusing upon the risks of aggressive BCs).

Fourthly, there were differences in exposures between men and women. These included distinct patterns of employment, differences in smoking rates and patterns (direct and passive ETS), hair dye use and hobbies. Given that most participants were male; our reported findings mostly reflect risk in men. Analysis of females only, suggests associations between high grade/high stage BC and workers undertaking electroplating and cutlery manufacture, and tasks such as degreasing and painting (p<0.05).

There are limitations to our work. Most importantly, the sample size was small and so this data should be viewed as hypothesis-generating, rather than definitive. Our aim was to undertake an explorative cohort study (rather than a clinical trial) and so no formal power calculation was performed. This reflects that very little is known about occupational risks and bladder cancer phenotypes and so powering was not possible. Our findings require validation in larger cohorts enriched for engineering and metal workers. Follow up was immature (median 8.4 years) in our series, and so many progressive tumours had not led to death in the participants. As such, we used stage and grade, progression and radical treatment, as surrogate measures for BC specific mortality. With longer follow up, we would look to see if these occupational tasks were associated with mortality or whether aggressive treatment could prevent this. Finally, the questionnaires were self-completed. Workers may have missed key exposures and others appeared more prominent that their actual workload. We asked participants to estimate the duration of each task, but these dates were often missing or very broad.

Conclusions

We identified multiple occupational tasks and contacts associated with high grade and high stage BC. Workers exposed to diesel fumes, employed in a garage, undertaking plumbing/gas fitting/ventilation, welding were more likely to have disease progression and receive radical treatment than others. These findings require validation and could be used to risk stratify persons with haematuria or follow up of non-invasive BC.

Supporting information

S1 Fig. Survival Curves for PLOS One.

(PDF)

S1 File. No logo Sheff Occup Questionnaire v4 08 11 11.s.

(PDF)

Data Availability

We are unable to release the full data set because it contains information that would allow individuals to be identified. Specifically, the granularity of detail is such that persons could cross gender, age, regional residence and occupational combinations to identify specific individuals with bladder cancer and their family history. Data access queries may be directed to Sarah Bottomley (contact via s.e.bottomley@sheffield.ac.uk).

Funding Statement

JWFC received project grant awards to perform this work from Yorkshire Cancer Research (yorkshirecancerresearch.org.uk, Numbers S310: Epigenetic carcinogenesis in the urothelium: development of a model system and examination of candidate occupational carcinogens and S385: The Yorkshire Cancer Research Bladder Cancer Patient Reported Outcomes Survey). The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References

  • 1.Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71(1):96–108. 10.1016/j.eururo.2016.06.010 [DOI] [PubMed] [Google Scholar]
  • 2.Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, et al. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. Eur Urol. 2020;77(5):583–98. 10.1016/j.eururo.2019.10.010 [DOI] [PubMed] [Google Scholar]
  • 3.Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447–61. 10.1016/j.eururo.2016.05.041 [DOI] [PubMed] [Google Scholar]
  • 4.Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer. 2013;108(7):1534–40. 10.1038/bjc.2013.106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol. 2018;74(6):784–95. 10.1016/j.eururo.2018.09.001 [DOI] [PubMed] [Google Scholar]
  • 6.Cumberbatch MG, Rota M, Catto JWF, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. European Urology. 2016;70(3):458–66. 10.1016/j.eururo.2015.06.042 [DOI] [PubMed] [Google Scholar]
  • 7.Cumberbatch MG, Cox A, Teare D, Catto JW. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015;1(9):1282–90. 10.1001/jamaoncol.2015.3209 [DOI] [PubMed] [Google Scholar]
  • 8.Cumberbatch M, Windsor-Shellard B, Catto JWF. The contemporary landscape of occupational bladder cancer within the United Kingdom: A meta-analysis of risks over the last 80 years BJU Int. 2017;119(1):100–9. 10.1111/bju.13561 [DOI] [PubMed] [Google Scholar]
  • 9.Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA: the journal of the American Medical Association. 2011;306(7):737–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bourke L, Bauld L, Bullen C, Cumberbatch M, Giovannucci E, Islami F, et al. E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks. Eur Urol. 2017;71(6):915–23. 10.1016/j.eururo.2016.12.022 [DOI] [PubMed] [Google Scholar]
  • 11.Porru S, Pavanello S, Carta A, Arici C, Simeone C, Izzotti A, et al. Complex relationships between occupation, environment, DNA adducts, genetic polymorphisms and bladder cancer in a case-control study using a structural equation modeling. PLoS One. 2014;9(4):e94566 10.1371/journal.pone.0094566 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rushton L, Bagga S, Bevan R, Brown TP, Cherrie JW, Holmes P, et al. Occupation and cancer in Britain. Br J Cancer. 2010;102(9):1428–37. 10.1038/sj.bjc.6605637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Noon AP, Pickvance SV, Catto JW. Occupational exposure to dye penetrants used for metal crack detection and the potential for bladder cancer. Occup Environ Med. 2012;69:300–1. [DOI] [PubMed] [Google Scholar]
  • 14.Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41. 10.1038/nrc3817 [DOI] [PubMed] [Google Scholar]
  • 15.Hurst C, Rosenberg J, Knowles M. SnapShot: Bladder Cancer. Cancer Cell. 2018;34(2):350– e1. 10.1016/j.ccell.2018.07.013 [DOI] [PubMed] [Google Scholar]
  • 16.Linton KD, Rosario DJ, Thomas F, Rubin N, Goepel JR, Abbod MF, et al. Disease Specific Mortality in Patients with Low Risk Bladder Cancer and the Impact of Cystoscopic Surveillance. Journal of Urology. 2013;189(3):828–33. 10.1016/j.juro.2012.09.084 [DOI] [PubMed] [Google Scholar]
  • 17.Catto JWF, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, et al. Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. Cancer Research. 2009;69(21):8472–81. 10.1158/0008-5472.CAN-09-0744 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018;174(4):1033 10.1016/j.cell.2018.07.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Noon AP, Martinsen JI, Catto JWF, Pukkala E. Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. Eur Urol Focus 2018. September;4(5):725–730. 2016. 10.1016/j.euf.2016.06.014 [DOI] [PubMed] [Google Scholar]
  • 20.Cartwright RA, Robinson MR, Glashan RW, Gray BK, Hamilton-Stewart P, Cartwright SC, et al. Does the use of stained maggots present a risk of bladder cancer to coarse fishermen? Carcinogenesis. 1983;4(1):111–3. 10.1093/carcin/4.1.111 [DOI] [PubMed] [Google Scholar]
  • 21.Beane Freeman LE, Cantor KP, Baris D, Nuckols JR, Johnson A, Colt JS, et al. Bladder Cancer and Water Disinfection By-product Exposures through Multiple Routes: A Population-Based Case-Control Study (New England, USA). Environ Health Perspect. 2017;125(6):067010 10.1289/EHP89 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018;73(4):560–9. 10.1016/j.eururo.2017.12.018 [DOI] [PubMed] [Google Scholar]
  • 23.Boffetta P, Silverman DT. A meta-analysis of bladder cancer and diesel exhaust exposure. Epidemiology. 2001;12(1):125–30. 10.1097/00001648-200101000-00021 [DOI] [PubMed] [Google Scholar]
  • 24.Benbrahim-Tallaa L, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of diesel-engine and gasoline-engine exhausts and some nitroarenes. Lancet Oncol. 2012;13(7):663–4. 10.1016/s1470-2045(12)70280-2 [DOI] [PubMed] [Google Scholar]
  • 25.Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–62. 10.1016/j.eururo.2014.01.006 [DOI] [PubMed] [Google Scholar]
  • 26.Larre S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013;63(6):1049–58. 10.1016/j.eururo.2012.12.062 [DOI] [PubMed] [Google Scholar]
  • 27.Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. European urology. 2011;59(6):1026–31. 10.1016/j.eururo.2011.03.027 [DOI] [PubMed] [Google Scholar]
  • 28.Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, et al. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011;108(4):546–52. 10.1111/j.1464-410X.2010.09971.x [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Eva Compérat

7 May 2020

PONE-D-20-10549

Occupational Bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes.

PLOS ONE

Dear Dr Reed

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by 12th of June. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Eva Compérat

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for including your ethics statement:

'All patients underwent informed consent in an ethically approved programme (South Yorkshire Research Ethics Committee approval number 10/H1310/73) before entry.'

a. Please amend your current ethics statement to confirm that your named institutional review board or ethics committee specifically approved this study.

b. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research

3. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses.

For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

4. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

5. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

6. Please include a caption for figure 1.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The submitted manuscript “Occupational Bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes.” by Reed et al. reports on 454 patients with urothelial bladder cancer, first diagnosed and treated between 02/2010 - 07/2012 at a single institution, the RHH (Sheffield).

Based on a patient-reported questionnaire, patients were evaluated for potential carcinogen exposure, whilst occupational classes were assigned using NYK and ISCO-1958 codes.

With a median follow-up of 8.4 years, the authors additionally report on tumor progression and the need of radical intervention. Outcome data was collected between 08/2018 - 10/2018.

This questionnaire-based evaluation, revealed multiple occupational tasks and contacts associated with high grade and high stage BC. Tumors were classified according to TNM and WHO 1973 criteria, therefore G1-G3 grading data has been reported.

Typical for an urothelial cancer population is the distribution between men and women with a ratio of roughly 4:1. Therefore, the reported data refers to mainly men, since all patients were included at time of initial diagnosis of bladder cancer.

The authors found differences in exposures between men and women, including

distinct patterns of employment, differences in smoking rates and patterns,

hair dye use and hobbies.

When only female patients were analyzed, the data suggests an association between high grade/high stage BC and workers undertaking electroplating and cutlery manufacture, and tasks such as degreasing and painting.

Although, the included patient cohort quite small to evaluate potential influences of exposure to occupational carcinogens, there are some interesting findings, worth to be reported.

Limitations of the manuscript are well described (e.g. estimated duration of each task), data reported and analyzed with appropriate methods, and outcome data revealed quite distinct differences for specific occupational groups.

Overall, an interesting and well-written manuscript, worth publication after minor revision:

Some comments:

- Please use BOLD for all significant values, which makes it easier to read tables.

- For Kaplan-Meier curves, please add “at risk numbers” on the bottom of the graphs.

Reviewer #2: Paper Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes by dr. Reed et al.

Very interesting study. I have just few comments, which, as I believe, can improve paper.

1, I would stress time of exposure. I believe it is very important point missed in discussion and even in abstract

2, I would suggest also hobby of participants. It is well known from other epidemiological studies......example can be psittacosis. It is indeed mostly occupational exposure linked disease, however substantial part of patients came from hobby sector (bird breeders, parrot lovers, etc, etc). Authors listed garage work as potential risk factor for aggressive disease course with recquired radical treatment. There are many car lovers, bikers who spend a substantial time in care of their gear and indeed they are haevily exposed to risk substanties. I think this should be at least discussed.

3, Is there any chance to check any link between variant histology (mostly highly aggressive tumors, sometimes with bland cytology-ie LG, like nested UC) and occupational exposure

Thank you

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS one occupational.docx

PLoS One. 2020 Oct 21;15(10):e0239338. doi: 10.1371/journal.pone.0239338.r002

Author response to Decision Letter 0


16 Jun 2020

3, Is there any chance to check any link between variant histology (mostly highly aggressive tumors, sometimes with bland cytology-ie LG, like nested UC) and occupational exposure

Answer: This is a very valuable point. Indeed some cases were defined as variants in their pathological reports. However, in 2010, the presence or absence of variant histology was not reliably reported in our hospital or in the UK (please see Urol Oncol. 2013 Nov;31(8):1650-5). As such, we are unable to reliably know whether each case had/did not have variant patterns and so have not reported this.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Amitava Mukherjee

4 Sep 2020

Occupational Bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes.

PONE-D-20-10549R1

Dear Dr. Reed,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Amitava Mukherjee, ME, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed the comments made by the reviewers and changed their manuscript accrodingly.

Reviewer #2: I believe this paper can help to solve questions about potential agents playing etiological role in development of UC. I do not have any further questions. Thank you

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Amitava Mukherjee

30 Sep 2020

PONE-D-20-10549R1

Occupational Bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes

Dear Dr. Reed:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Dr. Amitava Mukherjee

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Survival Curves for PLOS One.

    (PDF)

    S1 File. No logo Sheff Occup Questionnaire v4 08 11 11.s.

    (PDF)

    Attachment

    Submitted filename: PLOS one occupational.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    We are unable to release the full data set because it contains information that would allow individuals to be identified. Specifically, the granularity of detail is such that persons could cross gender, age, regional residence and occupational combinations to identify specific individuals with bladder cancer and their family history. Data access queries may be directed to Sarah Bottomley (contact via s.e.bottomley@sheffield.ac.uk).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES